The therapeutic management of rheumatoid arthritis has changed over the past 30 years, including a shift to methotrexate as the primary DMARD and the introduction of biologics. However, during the same time period, patients typically have presented with more comorbidities and higher BMIs. In this quiz, we focus on findings from a study recently published in the journal Rheumatology that examines trends in clinical and patient-reported outcomes in early RA.
The study included 2,701 patients and compared the five-year progression rates of clinical and patient-reported outcomes for patients diagnosed with RA in 1990, 2002 and 2010. It included clinical markers DAS28 and ESR. HAQ, visual analogue scale of pain and global health, and the Short-Form 36 were included as the patient-reported markers in the study.
Related article: "Fatigue Still Persists Long After Arthritic Flares Subside"
Reference: Lewis Carpenter, Elena Nikiphorou, Patrick D W Kiely, et al. “Secular changes in the progression of clinical markers and patient-reported outcomes in early rheumatoid arthritis.” Rheumatology. January 3, 2020. doi.org/10.1093/rheumatology/kez635